NEW YORK, Jan 4, 2026, 14:49 ET — Market closed
- Johnson & Johnson board declared a $1.30-per-share quarterly dividend, payable March 10.
- JNJ shares last closed at $207.35 on Jan. 2, up 0.19%.
- Next catalyst is the company’s Jan. 21 fourth-quarter earnings call, with U.S. jobs and inflation data due earlier in the month.
Johnson & Johnson on Friday declared a quarterly cash dividend of $1.30 per share, payable March 10 to shareholders of record at the close of business on Feb. 24, the company said. The ex-dividend date — when shares begin trading without the right to that payout — is also Feb. 24.
At Friday’s close, the payout implies an annual dividend yield of about 2.5%, keeping the healthcare bellwether in focus for income investors as U.S. trading resumes on Monday. Dividend schedules can influence near-term positioning when funds rebalance early-year portfolios.
The next major company catalyst is Jan. 21, when Johnson & Johnson will host its fourth-quarter earnings call at 8:30 a.m. ET. Traders will also be parsing U.S. data, with the employment report due Jan. 9 and the consumer price index set for Jan. 13.
JNJ shares last closed up 0.19% at $207.35 on Jan. 2, with about 6.33 million shares traded. The stock is up about 43.8% over the past year and sits roughly 3.6% below its 52-week high, according to Investing.com data.
On the chart, traders are watching whether the stock can hold above its 50-day moving average near $200, a level often treated as a near-term support marker. J&J is also well above its 200-day moving average around $174, a longer-term trend gauge for many investors.
Earnings will put the focus back on 2026 guidance, momentum in the company’s drug and medical-device businesses, and any update on pricing and competitive pressures across key franchises. Investors will also listen for management’s commentary on margins and currency effects, which can swing quarter-to-quarter comparisons.
With jobs and inflation readings returning to the calendar, rate expectations are back in play. That matters for steady dividend payers like Johnson & Johnson because their relative appeal tends to rise when investors expect lower interest rates and seek predictable cash returns.
One risk is litigation. A Baltimore jury in late December awarded more than $1.5 billion in a talc-related case, and J&J’s worldwide vice president of litigation Erik Haas said the company would “immediately appeal” the verdict. Reuters
With U.S. markets shut for the weekend, investors head into Monday balancing the dividend backdrop against a busy January of macro data and earnings. For Johnson & Johnson stock, the next hard catalyst is the Jan. 21 quarterly report and call.
